Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin by PRADO, Kleber et al.
www.bjid.com.br
362 BJID 2008; 12 (October)
Received on 15 April 2008; revised 20 September 2008.
Address for correspondence: Dr. Kleber Dias do Prado. Emilio Ribas
Infectious Diseases Institute, Scientific Department. Av. Dr. Arnaldo
165, São Paulo, SP, Brazil, Zip code: 01246-900. E-mail:
kdiasdoprado@gmail.com - Phone/Fax: (55 11) 3896-1241.
The Brazilian Journal of Infectious Diseases        2008;12(5):362-367.
© 2008 by The Brazilian Journal of Infectious Diseases and Contexto
Publishing. All rights reserved.
Histological Response Study of Chronic Viral Hepatitis C Patients Treated With Interferon Alone or
Combined With Ribavirin
Kleber Prado1, Rosely Patzina2, Denise Bergamaschi3 and Roberto Focaccia1
1Viral Hepatitis Clinic - Emilio Ribas Infectious Diseases Institute; 2Department of Pathology – Emilio Ribas Infectious Diseases Institute;
3Department of Statistics - Public Health College – University of São Paulo; São Paulo, SP, Brazil
Chronic hepatitis C is often a progressive, fibrotic disease that can lead to cirrhosis and other complications. The
recommended therapy is a combination of interferon and ribavirin. Besides its antiviral action, interferon is
considered to have antifibrotic activity. We examined the outcome of hepatic fibrosis and inflammation in chronic
hepatitis C patients who were non-responders to interferon. We made a case series, retrospective study, based on
revision of medical records and reassessment of liver biopsies. For inclusion, patients should have been treated with
interferon alone or combined with ribavirin, with no virological response (non responders and relapsers) and had a
liver biopsy before and after treatment. Histological evaluation included: i-outcome of fibrosis and
necroinflammation; ii-annual fibrosis progression rate evaluation, before and after treatment. Seventy-five patients
were included. Fifty-seven patients (76%) did not show progression of fibrosis after treatment, compared to six (8%)
before treatment (p < 0.001). The mean annual fibrosis progression rate was significantly reduced after treatment
(p = 0.036). Inflammatory activity improved in 19 patients (25.3%). The results support the hypothesis of an antifibrotic
effect of interferon-based therapy, in non-responder patients. There was evidence of anti-inflammatory effects of
treatment in some patients.
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Hepatitis C virus (HCV) infection is a major worldwide
public health issue. It is estimated that between 170 and 250
million people are chronic carriers [1]. There is no available
information about the prevalence rate of chronic hepatitis C
in Brazil, although Focaccia et al. found an estimated prevalence
of 1.42% in São Paulo City, rising to over 3% within the 30 and
older age group. We examined the medical records of patients
from 2 to 80 years old in a serological survey of a stratified,
randomized and residence-based population [2].
HCV infection becomes a chronic disease in a large
proportion of patients, ranging from 55% to 90%; it has a
progressive fibrotic nature. Up to 20% of the cases may
culminate in cirrhosis; which may cause complications, such
as hepatocellular carcinoma and end-stage liver disease [3-5].
The combination of pegylated interferon (PEG) and ribavirin,
which is currently the best available treatment, given during
48 weeks, only reaches a sustained virological response (SVR)
in 54%-56% of naive patients [6,7]. Non-responder patients
to interferon alone or in combination with ribavirin have an
even smaller frequency of virological response [8]. Currently,
for non-responders to a combination of PEG and ribavirin,
there is no consensus therapeutic option that considers the
histological response among treatment efficacy end-points
[3,9-11].
Several studies have demonstrated the inherent
antifibrinogenic action of interferon, which is not related to
its antiviral and anti-inflammatory effects [12-16]. Furthermore,
it has also been proven through several clinical trials that
interferon-based treatments provoke histological
improvements, even in virological non-responders [17-22]. We
evaluated hepatic fibrosis and necro-inflammatory activity
progression in chronic hepatitis C patients who were non-
responders to interferon-based treatments or relapsers.
Material and Methods
A retrospective study was made of chronic hepatitis C
patients who had been treated at the Viral Hepatitis Clinic of
the Emilio Ribas Infectious Diseases Institute (ERIDI), in São
Paulo, Brazil, from January 1997 to December 2002. We reviewed
patient medical records to collect demographic,
anthropometric, epidemiological and clinical information, as
information on liver biopsies. The study protocol was
approved by ERIDI’s Ethics Committee.
We identified 8,192 medical records of hepatitis patients within
this period. A preliminary analysis ruled out acute hepatitis cases,
HIV or HVB coinfections, HCV spontaneous clearance, patients
who had never been under treatment or had not undergone liver
biopsy before and after treatment. The remaining 615 medical
charts were reviewed for inclusion. The inclusion criteria were: 1
– previous treatment for at least six months with interferon-alfa,
with or without ribavirin, using standardized doses and routes of
administration [6,7,23,24]; 2 – a liver biopsy performed or reviewed
by an ERIDI pathologist, performed within six months prior to
treatment and at least six months after treatment; 3 – non-response
to treatment or relapse. The exclusion criteria were: 1 – chronic
liver diseases not related to HCV; 2 – current alcohol or illegal
drug abuse; 3 - use of hepatotoxic or immunosuppressive drugs;
4 - immunosuppressive illness and HIV coinfection.
Non response was defined as detectable HCV RNA by
PCR technique (Amplicor 2.0 version kits, with a lower limit of
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sensitivity of 50 IU/mL) at the end of treatment and relapse
based on undetectable serum HCV-RNA using the same
technique at the end of treatment, which became detectable
six months later. To determine the HCV genotype, the INNO-
LIPA HCV II technique was used, with the Versant kit (Lipa)®.
Liver biopsies were read blind, always by the same
pathologist from the Department of Pathology of ERIDI,
applying the METAVIR score. Fibrosis qualitative evolution
was evaluated by making a fibrosis stage comparison between
the two biopsy tests (before and after treatment), with three
possible outcomes: 1 – progression (after-treatment fibrosis
stage more advanced than before-treatment stage); 2 –
stabilization (after-treatment fibrosis stage not changed
compared to before-treatment stage); and 3 – regression (after-
treatment fibrosis stage lower than before-treatment stage).
Patients classified as stage four (cirrhosis) at the first liver
biopsy were classified in the progression category whenever
decompensated cirrhosis was identified. In such cases, a new
biopsy was not required. Otherwise, patients were designated
in the non-progression category if the new biopsy did not
demonstrate regression.
The annual fibrosis progression rate, both pre and post-
treatment, was calculated based on the following definitions:
1- pre-treatment annual fibrosis progression rate =the ratio
between fibrosis stage measured in METAVIR units at the
first biopsy (pre-treatment) and the estimated time of infection
in years; 2 – post-treatment annual fibrosis progression rate
= the ratio between the difference in fibrosis stage measured
in METAVIR units of the pre and post-treatment biopsies and
the delay between the two biopsies in months multiplied by
12 [4,18].
The calculation of the probable infection date, and
consequently, the time of infection, was based on: a – for
transfusional infections, the date of the first blood and/or
plasma derived products transfusion was considered, if the
patient had gone through more than one transfusion session;
b – for infection caused by injectable drugs, the first year of
use of such drugs [12,25,26]. For any other cause of HCV
infection, only infection dates based on unequivocal evidence
of a temporal relation between exposure and HCV infection
were used.
The liver biopsy samples were at least 10mm long or had
six portal tracts [27]. The liver tissue fragments were colored
by hematoxilin-eosine, Masson’s trichrome, Perls and
reticuline.
Statistical Analysis
For comparison of proportions (pre and post-treatment
situations), we used the McNemar test for dependent samples
and the Pearson’s chi-square for independent samples. For
mean values comparison, we used the “Student” t test (on
independent samples) and a paired student t (on dependent
samples), when there were only two means involved in the
comparison. When the variables did not conform to a normal
distribution, we used the Wilcoxon signed-rank test [28], for
population comparisons. The statistical computer program
Stata was used for this analysis [29]. Statistical decisions were
made considering the descriptive value of the tests (p value).
Results
Seventy-five patients met the inclusion criteria. Table 1
shows the main characteristics of the 75 patients included in
this study.
Seventy-nine percent of the patients had undergone a
liver biopsy one year or more after the end of treatment (median
time: 20 months; range: 1 - 67 months). Seventy-six percent of
patients showed stabilization or regression of fibrosis (no
progression) at the second liver biopsy (Table 2 and Figure
1). Before treatment, the vast majority of patients had evidence
of fibrosis progression (fibrosis stage > 0). In contrast, after
treatment, most patients displayed a tendency towards no
progression (p< 0.001), at least over the period the patients
were observed (Figure 2).
A significant association was found between fibrosis
qualitative evolution and pre-treatment fibrosis stages
(p=0.005), with higher rates of progression among patients at
stages 0, 1 and 2, and regression among patients at stages 3
and 4 (Table 3).
The pre-treatment annual fibrosis progression rate was
defined for 42 patients. There was a mean rate of 0.096 FMU/
year (fibrosis METAVIR units per year) (CI 95%: 0.075 – 0.117
FMU/year), a median value of 0.096 FMU/year, with minimum
and maximum values of 0.000 and 0.272 FMU/year, respectively.
The post-treatment fibrosis annual progression rate was
calculated for 75 patients. There was a mean rate of 0.007
FMU/year, (CI 95%: -0.066 – 0.081 FMU/year), a median value
of 0.000 FMU/year, with minimum and maximum values of -
1.500 and 0.827 FMU/year, respectively. The paired pre and
post –treatment rate analyses, restricted to the 42 patients
with known pre-treatment rates, showed a significant decrease
of the fibrosis annual progression rate. The post-treatment
mean rate in these patients was -0.005 FMU/year (CI 95%: -
0.088 – 0.078 FMU/year); there was a difference of 0.101 FMU/
year (CI 95%: 0.007 – 0.194FMU/year, p=0.036) between the
mean rates (paired Student-t test).
The post-treatment fibrosis annual progression rate in
comparison with the fibrosis stage on the pre-treatment biopsy
showed a significantly higher decrease of this progression
among the patients that were in an advanced stage of fibrosis
(F3/F4) at the time of the pre-treatment biopsy when compared
to those who had had mild-to-moderate fibrosis (F0/F1/F2)
(p=0.0143). Among the 31 patients that had showed mild-to-
moderate fibrosis at pre-treatment, the mean decrease in
fibrosis progression after treatment was 0.034 FMU/year, while
in the 11 patients who had shown advanced fibrosis pre-
treatment, the mean decrease was 0.287 FMU/year.
Table 4 summarizes the information about the progress in
inflammatory activity. Table 5 shows the progression in
inflammatory activity according to different ranks of fibrosis
qualitative progress. There were significant differences among
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patients who had shown fibrosis regression and progression
(p=0.024), with a higher regression rate and a lower progression
rate of liver inflammation in the former compared to the latter.
There was information available about previous alcohol
consumption in the medical records of the 44 patients: 14
(31.8%) reported no alcohol use, 15 (34.1%) reported
occasional use and 15 (34.1%) admitted daily use of alcoholic
beverages. Statistical differences in alcohol consumption
between mild-to-moderate (F0/F1/F2) and advanced (F3/F4)
fibrosis patients were not found (p=0.660). Among the 15
patients who admitted daily use of alcohol, 13 (86.7%) showed
mild-to-moderate liver fibrosis before treatment.
Discussion
The main obstacle against including patients was the
unavailability, for various reasons, of liver biopsies for revision
by the pathologist. This occurred in 355 cases. Some other
reasons for not including patients were: patients that had
been treated by other health facilities outside of the ERIDI;
patients who had been under irregular treatment, with
discontinuity or reduced doses of the treatment drugs; patients
whose time interval between the first biopsy and treatment
exceeded one year; and patients who had made the liver biopsy
less than six months after the end of treatment.
As a retrospective case series on a medical records revision
basis, this study has some serious limitations. The most
important of them comes from the lack of standardization of
the medical record information. Another weakness originates
from the adoption of a consensual and universal treatment
that has prevented the use of a control group of patients
without treatment for comparison. Lastly, the period of time
during which the patients were under observation after
treatment was significantly shorter than the pre-treatment
period. This may overestimate the therapeutic benefits in cases
of slowly progressing diseases.
Statistical associations were found among treatment,
hepatic fibrosis non-progression and decreases in the annual
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Table 1. Characteristics of the patients.
Male gender – no. (%) 49 (65.3)
Age at 1st biopsy – years (mean) 43.5 ± 9.8
≤ 40 years - nº (%) 24 (32)
> 40 years - nº (%) 51 (68)
Weight – Kg (mean) 77.2 ± 14.8
Mode of infection - nº (%)
Blood transfusion 30 (40.0)
Injection drug use 8 (10.7)
Other sources * 7 (9.3)
Unknown 30 (40.0)
Response to treatment - nº (%)†
RL 11 (14.7)
NR 64 (85.3)
Genotype HCV - nº (%)
1 41 (54.7)
2  1 (1.3)
3 8 (10.7)
Unknown 25 (33.3)
Category of treatment - nº (%)‡
IFN 35 (46.7)
IFN/RBV 54 (72.0)
PEG/RBV 2 (2.7)
Total exposition to IFN – no. (%)
≤ 12 months 43 (57.3)
13-24 months 27 (36.0)
> 24 months 5 (6.7)
*Occupational exposure to blood (needles, contaminated
syringes) or sexual relationship with an infected individual. † RL
– relapser; NR – non-responder. ‡ IFN – interferon; RBV –
ribavirin; PEG – pegylated interferon.
Table 2. Post-treatment fibrosis qualitative evolution.
Evolution N %
N* 43 57.3
P 18 24.0
R 14 18.7
Total 75 100.0
*N – non-progression (stabilization) P – progression;
R – regression.
Table 3. Post-treatment fibrosis qualitative evolution according to pre-treatment fibrosis stages.
Table 4. Qualitative evolution of inflammatory activity.
Evolution N %
Non-regression* 56 74.7
Regression 19 25.3
Total 75 100.0
*Non-regression: patients with impairment or
stabilization of inflammatory activity.
Pre-treatment fibrosis stages Fibrosis evolution n (%) P value
Non progression Progression Regression
Stages 0, 1 and 2 32 (58.2) 17 (30.9) 6 (10.9) 0.005*
Stages 3 and 4 11 (55.0) 1 (5.0) 8 (40.0)
Total 43 (57.3) 18 (24.0) 14 (18.7)
* Pearson’s chi-square.
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Figure 1. Pre and post-treatment fibrosis stage. The shadow zone indicates stabilization of fibrosis. Above and to the right of the
shadow zone indicates fibrosis progression. Below and to the left indicates fibrosis regression.
Figure 2. Fibrosis progression before and after treatment.
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Table 5. Inflammatory activity evolution according to fibrosis evolution.
Fibrosis evolution Inflammatory activity evolution - N (%)
Regression Stabilization Progression Total
Regression 7 (50)* 7 (50) 0 14 (100)
Stabilization 10 (23.3) 25 (58.1) 8 (18.6) 43 (100)
Progression 2 (11.2) 8 (44.4) 8 (44.4)* 18 (100)
Total 19 40 16 75
*p = 0.024 (Pearson’s chi-square).
Post- treatment fibrosis – n (%)
Pre-
treatment 
fibrosis
0 1 2 3 4
0 3
(4.0)
2
(2.7)
 1
(1.3)
1 3
(4.0)
14
(18.7)
4
(5.3)
1
(1.3)
1
(1.3)
2 3
(4.0)
15
(20.0)
6
(8.0)
2
(2.7)
3 1
(1.3)
3
(4.0)
8
(10.7)
1
(1.3)
4 4
(5.3)
3
(4.0)
0
10
20
30
40
50
60
70
80
Pre-treatment Post-treatment
No progression
Progression
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fibrosis progression rate, in comparison with the chronic
hepatitis C natural history. Similar results have been found in
other studies [8,18,20,30].
The observation of hepatic fibrosis regression in 14 patients
is a very important piece of information, since spontaneous
regression of hepatic fibrosis is not usually seen in patients
without treatment. We speculate that the regression in fibrosis
is due to an antifibrogenic effect of interferon, regardless of its
antiviral action. Poynard et al. demonstrated that hepatitis C is
indeed a progressive fibrotic disease, which is the reason for
its morbidity and mortality [4]. Therefore, a therapeutic
intervention to decrease or revert hepatic fibrosis progression
will probably have a relevant clinical impact. In our study, seven
out of 14 patients with fibrosis regression also showed post-
treatment inflammatory activity regression, while the other
seven patients remained at the same activity level. It seems
reasonable to attribute fibrosis regression in the latter group to
an intrinsic antifibrogenic effect.
On the other hand, the relevant fibrosis stabilization rates
in patients with mild-to-moderate, as well as advanced
fibrosis (58.2% and 55.0%, respectively), are probably due
to the anti-inflammatory action of ribavirin and interferon.
As a matter of fact, among the 75 patients, only 21 (28%) had
made use of standard interferon (IFN) alone, while the other
54 (72%), had made use of ribavirin along with IFN or PEG,
with the possibility that the ribavirin indirectly facilitated
the interferon antifibrogenic effect through its anti-
inflammatory action.
It has been noticed among patients with advanced
fibrosis before treatment, that there is a higher proportion
of patients with fibrosis regression and a larger reduction
in the annual fibrosis progression rate, after treatment in
comparison with patients who had mild-to-moderate
fibrosis. Again, there was a good correlation between the
qualitative evolution and the annual fibrosis progression
rate. Poynard et al. found similar results among 1,509 French
patients, though they used a different methodology for
defining mild-to-moderate and advanced fibrosis [20].
However, in our study, the small number of patients with
advanced fibrosis did not make it possible to make
conclusions from the results.
Treatment effects on inflammatory activity evolution were
less evident. About 75% of the patients worsened or did
not present any variation in hepatic inflammatory activity,
in disagreement with several other studies that reported
on the anti-inflammatory effect of chronic hepatitis C
treatment [8,17,31-35]. Even so, 66% of the patients showed
null or mild degrees of inflammatory activity after treatment,
foreseeing an absence of fibrosis progression on the short
and probably the mid-term. Studies of Poynard et al. about
the natural history of hepatitis C show that the degree of
inflammatory activity is less associated with the time of
disease than fibrosis, which reflects the oscillating
inflammatory activity due to infection [4]. For a better
measurement of the treatment’s impact upon inflammatory
liver activity, a post-treatment hepatic biopsy should have
been made, preferably right away after the end of the
treatment, or within the first six months, as has been done
in other studies [17,32-34].
Finally, we did not find histological benefits for longer
exposure to interferon in terms of fibrosis or inflammatory
activity improvements. A possible reason was the small
number of patients exposed to interferon over 24 months.
In conclusion, the significant proportion of patients
who have not shown fibrosis progression, associated with
the significant fibrosis progression rate reduction after
an interferon-based treatment, support the hypothesis of
an antifibrogenic effect of interferon, associated or not
with ribavirin, in patients that still carry the virus after
treatment. We conclude that long-term reduced dosages
of interferon for patients with advanced fibrosis and who
have no virological response to classic treatment would
help prevent liver damage.
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